FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4311472854> ?p ?o ?g. }

• W4311472854 endingPage "151" @default.
• W4311472854 startingPage "141" @default.
• W4311472854 abstract "Utreloxastat (PTC857) is a 15-lipoxygenase inhibitor being developed to treat amyotrophic lateral sclerosis. This first-in-human study investigated the safety and pharmacokinetics of utreloxastat in healthy volunteers (N = 82) in a double-blind, placebo-controlled trial. The effects of a single ascending dose (100-1000 mg), multiple ascending doses (150-500 mg), and food (500 mg) on the pharmacokinetics and safety of utreloxastat were evaluated. Following single doses, the time to maximum plasma concentration (Cmax ) was observed ≈4 hours after dosing and the terminal half-life ranged from 20 to 25.3 hours. The Cmax and area under the concentration-time curve (AUC) increased slightly over dose proportionally. Following multiple doses (once daily/twice daily), the apparent clearance reduced and terminal half-life was ≥33 hours. There was no apparent difference of exposure following morning or evening doses. Varying diets increased the Cmax and AUCs of utreloxastat but did not alter time to Cmax . There were no gender-based differences in exposure. Utreloxastat showed no marked safety signal following single doses up to 1000 mg and multiple doses over 14 days of 500 mg once daily or 250 mg twice daily. The results support further development of utreloxastat for the treatment of patients with amyotrophic lateral sclerosis at a 250-mg twice-daily dose administered with food." @default.
• W4311472854 created "2022-12-26" @default.
• W4311472854 creator A5009962242 @default.
• W4311472854 creator A5011426512 @default.
• W4311472854 creator A5013585825 @default.
• W4311472854 creator A5016232050 @default.
• W4311472854 creator A5019100820 @default.
• W4311472854 creator A5024909707 @default.
• W4311472854 creator A5027918265 @default.
• W4311472854 creator A5040799420 @default.
• W4311472854 creator A5047899193 @default.
• W4311472854 creator A5056763549 @default.
• W4311472854 creator A5063286803 @default.
• W4311472854 creator A5067627495 @default.
• W4311472854 creator A5089214981 @default.
• W4311472854 date "2022-12-14" @default.
• W4311472854 modified "2023-10-16" @default.
• W4311472854 title "First‐in‐Human Studies of Pharmacokinetics and Safety of Utreloxastat (PTC857), a Novel 15‐Lipooxygenase Inhibitor for the Treatment of Amyotrophic Lateral Sclerosis" @default.
• W4311472854 cites W1967275179 @default.
• W4311472854 cites W1991162461 @default.
• W4311472854 cites W2076745180 @default.
• W4311472854 cites W2091902711 @default.
• W4311472854 cites W2110184140 @default.
• W4311472854 cites W2518689955 @default.
• W4311472854 cites W2597399186 @default.
• W4311472854 cites W2759112714 @default.
• W4311472854 cites W2767148810 @default.
• W4311472854 cites W2802800214 @default.
• W4311472854 cites W2894231856 @default.
• W4311472854 cites W2913609543 @default.
• W4311472854 cites W2953909155 @default.
• W4311472854 cites W3195728368 @default.
• W4311472854 doi "https://doi.org/10.1002/cpdd.1203" @default.
• W4311472854 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36516010" @default.
• W4311472854 hasPublicationYear "2022" @default.
• W4311472854 type Work @default.
• W4311472854 citedByCount "0" @default.
• W4311472854 crossrefType "journal-article" @default.
• W4311472854 hasAuthorship W4311472854A5009962242 @default.
• W4311472854 hasAuthorship W4311472854A5011426512 @default.
• W4311472854 hasAuthorship W4311472854A5013585825 @default.
• W4311472854 hasAuthorship W4311472854A5016232050 @default.
• W4311472854 hasAuthorship W4311472854A5019100820 @default.
• W4311472854 hasAuthorship W4311472854A5024909707 @default.
• W4311472854 hasAuthorship W4311472854A5027918265 @default.
• W4311472854 hasAuthorship W4311472854A5040799420 @default.
• W4311472854 hasAuthorship W4311472854A5047899193 @default.
• W4311472854 hasAuthorship W4311472854A5056763549 @default.
• W4311472854 hasAuthorship W4311472854A5063286803 @default.
• W4311472854 hasAuthorship W4311472854A5067627495 @default.
• W4311472854 hasAuthorship W4311472854A5089214981 @default.
• W4311472854 hasBestOaLocation W43114728541 @default.
• W4311472854 hasConcept C112705442 @default.
• W4311472854 hasConcept C121332964 @default.
• W4311472854 hasConcept C126322002 @default.
• W4311472854 hasConcept C1276947 @default.
• W4311472854 hasConcept C142724271 @default.
• W4311472854 hasConcept C19720800 @default.
• W4311472854 hasConcept C204787440 @default.
• W4311472854 hasConcept C22979827 @default.
• W4311472854 hasConcept C27081682 @default.
• W4311472854 hasConcept C2776476923 @default.
• W4311472854 hasConcept C2777288759 @default.
• W4311472854 hasConcept C2779134260 @default.
• W4311472854 hasConcept C2779319286 @default.
• W4311472854 hasConcept C2780596555 @default.
• W4311472854 hasConcept C42219234 @default.
• W4311472854 hasConcept C71924100 @default.
• W4311472854 hasConcept C98274493 @default.
• W4311472854 hasConceptScore W4311472854C112705442 @default.
• W4311472854 hasConceptScore W4311472854C121332964 @default.
• W4311472854 hasConceptScore W4311472854C126322002 @default.
• W4311472854 hasConceptScore W4311472854C1276947 @default.
• W4311472854 hasConceptScore W4311472854C142724271 @default.
• W4311472854 hasConceptScore W4311472854C19720800 @default.
• W4311472854 hasConceptScore W4311472854C204787440 @default.
• W4311472854 hasConceptScore W4311472854C22979827 @default.
• W4311472854 hasConceptScore W4311472854C27081682 @default.
• W4311472854 hasConceptScore W4311472854C2776476923 @default.
• W4311472854 hasConceptScore W4311472854C2777288759 @default.
• W4311472854 hasConceptScore W4311472854C2779134260 @default.
• W4311472854 hasConceptScore W4311472854C2779319286 @default.
• W4311472854 hasConceptScore W4311472854C2780596555 @default.
• W4311472854 hasConceptScore W4311472854C42219234 @default.
• W4311472854 hasConceptScore W4311472854C71924100 @default.
• W4311472854 hasConceptScore W4311472854C98274493 @default.
• W4311472854 hasIssue "2" @default.
• W4311472854 hasLocation W43114728541 @default.
• W4311472854 hasLocation W43114728542 @default.
• W4311472854 hasOpenAccess W4311472854 @default.
• W4311472854 hasPrimaryLocation W43114728541 @default.
• W4311472854 hasRelatedWork W188574239 @default.
• W4311472854 hasRelatedWork W2032082849 @default.
• W4311472854 hasRelatedWork W2080310850 @default.
• W4311472854 hasRelatedWork W2088355176 @default.
• W4311472854 hasRelatedWork W2142751397 @default.
• W4311472854 hasRelatedWork W2162426235 @default.
• W4311472854 hasRelatedWork W2413092544 @default.

• next